A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
Megadott ok: Termination due to challenges related to the operational feasibility of the study, taking into account the current epidemiology and declining hospitalization rates for severe COVID-19.
Key facts
- Where
- Cooperstown és New York, Egyesült ÁllamokSee the 2 sites
- Phase
- 2. fázis
Where in Egyesült Államok
- Bassett Medical CenterCooperstown, Egyesült ÁllamokNo longer taking part
- Harlem Hospital CenterNew York, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT05545319
- Record updated
- 2023. március 1.
- Original description
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19Read full original descriptionShow less
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR COMPARED WITH PLACEBO/RITONAVIR FOR THE TREATMENT OF SEVERE COVID-19 IN HOSPITALIZED PARTICIPANTS WHO ARE IMMUNOCOMPROMISED OR AT INCREASED RISK FOR SEVERE COVID-19 OUTCOMES
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
Inclusion: Meeting 1 of the 2 categories of COVID-19 risk:; Category A: Immunocompromised; Category B: Non-Immunocompromised, but with ≥2 risk factors; Onset of signs/symptoms attributable to COVID-19 ≤10 days prior to the day of randomization for non-immunocompromised participants (Category B); Confirmed SARS-CoV-2 infection as determined by Reverse transcription polymerase chain reaction (RT-PCR) or acceptable test method performed by a health care provider in any specimen collected within 48 hours prior to randomization; Hospitalized for inpatient care for the treatment of clinical manifestations of severe COVID-19; Requirement for oxygen supplementation (via nasal cannula, mask, non-invasive ventilation [NIV] or high flow oxygen) to maintain SpO2 ≥94% at the time of Screening and Randomization.
Exclusion: Receiving dialysis of any kind or severe renal impairment; Critical illness, defined by ≥1 of the following:; Multi-organ dysfunction/failure; Hemodynamically unstable, eg. septic shock, cardiac failure or requiring vasopressors; History of severe chronic liver disease; Use of nirmatrelvir/ritonavir as an outpatient to treat the current COVID-19 related illness ≤7 days of randomization; Requirement for mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at randomization, or likely to require intermittent mandatory ventilation (IMV) or ECMO within 12 hours of randomization ; Participant not expected to survive 24 hours from time of randomization.